The TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global blockbuster drugs and have dominated the global pharmaceutical market landscape for many years. The report includes classification of the pipeline by type of molecules such monoclonal antibody, polyclonal antibody, recombinant fusion protein, and a small molecule.
Around 45% of TNF inhibitors in pipeline are being evaluated for the treatment of RA. According to the Centers for Disease Control and Prevention (CDC), around 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040.
Covered in this report
The report covers the present scenario and the growth prospects of the TNF inhibitors. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's TNF Inhibitors - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
- Boehringer Ingelheim
- Mochida Pharmaceutical
- How will the market evolve during the forecast period?
- What are the major parameters impacting the market?
- What are the key market trends?
- What are the challenges to market growth?
- Who are the key companies in this market space?
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: TNF INHIBITOR INSIGHT
PART 06: PIPELINE MOLECULES BY VENDORS
PART 07: COMPARATIVE ANALYSIS
- Late-stage molecules (filed and Phase III)
- Mid-stage molecules (Phase II)
- Early-stage molecules (Phase I and IND)
- Pre-clinical molecules
- Status unknown molecules
- Discontinued products
- Dormant products
PART 09: MARKETED DRUGS
- Top selling drugs
- Therapeutic assessment based on therapy
- Therapeutic assessment based on RoA
- Therapeutic assessment based on molecule type
- Active companies: Category and parameters
- List of abbreviations
Exhibit 01: An overview of pipeline molecules 2017
Exhibit 02: Pipeline landscape
Exhibit 03: Pipeline molecules by vendors 2017
Exhibit 04: Pipeline molecules in different developmental stages 2017
Exhibit 05: Pipeline molecules in different developmental stages 2017 (%)
Exhibit 06: Late-stage molecules by different vendors 2017
Exhibit 07: Overview: PF-06438179
Exhibit 08: Overview: BI 695501
Exhibit 09: Overview: GP2017
Exhibit 10: Overview: SB5
Exhibit 11: Overview: LBEC0101
Exhibit 12: Overview: TuNEX (etanercept)
Exhibit 13: Overview: BCD-057
Exhibit 14: Clinical trials description of BCD-057
Exhibit 15: Overview: CIMZIA
Exhibit 16: Clinical trials description for CIMZIA
Exhibit 17: Overview: PF-06410293
Exhibit 18: Overview: ABP 710
Exhibit 19: Overview: CHS-0214
Exhibit 20: Overview: IBI 303
Exhibit 21: Overview: LBAL
Exhibit 22: Overview: OPRX-106
Exhibit 23: Overview: ATN-103
Exhibit 24: Overview: TNF Oral
Exhibit 25: Overview: AVX 470
Exhibit 26: Overview: T0001
Exhibit 27: Overview: HL036
Exhibit 28: Overview: Adalimumab
Exhibit 29: Overview: BX2922
Exhibit 30: Overview: AZD9773
Exhibit 31: Overview: Adalimumab biosimilar
Exhibit 32: Overview: Etanercept biosimilar
Exhibit 33: Analysis of pipeline molecules by indication 2017
Exhibit 34: Overview of top three indications 2017
Exhibit 35: Overview: HUMIRA
Exhibit 36: Overview: Remicade
Exhibit 37: Overview: CIMZIA
Exhibit 38: Overview: Enbrel
Exhibit 39: Assessment by monotherapy products 2017
Exhibit 40: Assessment by RoA 2017
Exhibit 41: Assessment by molecule type (number of molecules) 2017
Exhibit 42: Assessment by molecule type (%) 2017
Exhibit 43: Active companies: Category and parameters 2017
Exhibit 44: Segmentation of companies 2017
Exhibit 45: Overview: Ablynx 2017
Exhibit 46: Overview: Amgen 2016
Exhibit 47: Overview: Avaxia Biologics 2016
Exhibit 48: Overview: BIOCAD 2016
Exhibit 49: Overview: BioXpress Therapeutics 2017
Exhibit 50: Overview: Coherus Biosciences 2017
Exhibit 51: Overview: Dermira 2016
Exhibit 52: Overview: Hanall BioPharma 2017
Exhibit 53: Overview: Innovent Biologics
Exhibit 54: Overview: Levolta Pharmaceuticals 2016
Exhibit 56: Overview: Mochida Pharmaceutical 2017
Exhibit 57: Overview: Mycenax Biotech 2017
Exhibit 58: Overview: Novartis 2016
Exhibit 59: Overview: Pfizer 2016
Exhibit 60: Overview: Protalix 2016
Exhibit 61: Overview: Samsung Bioepis 2016
Exhibit 62: Overview: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical 2016
The author of the report recognizes the following companies in the TNF inhibitors: Pfizer, Boehringer Ingelheim, Novartis, Amgen, Mochida Pharmaceutical, Hanall, and BioPharma.
TNF is involved in a wide range of autoimmune and inflammatory disorders such as rheumatoid arthritis (RA), ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Besides its biological importance, TNF is important in terms of commercial value as anti-TNF antibody medicines are one of the world’s best-selling medicines.
For instance, adalimumab (anti-TNF antibody) is one of the top-selling medicines with global sales of over $10,000 million per year. The total annual sales of various anti-TNFs/anti-TNF receptor (TNFR) drugs are exceeding $25,000 million globally, thus making anti-TNFs as one of the most profitable drug classes. The importance of TNF inhibitors becomes much more relevant due to its use in the treatment of various health conditions.
Most of the TNF inhibitors being evaluated currently in the pipeline are biologicals. Moreover, six of the top 10 best-selling pharmaceuticals are biologicals and nearly half of all clinical trials are conducted for injectable proteins related to antibodies. Due to its effective outcome in the treatment of autoimmune and inflammatory disorders, TNF inhibitors are considered as the physicians first choice of treatment globally for such devastating health conditions.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.